JPRN-UMIN000011671
Recruiting
Phase 1
Phase I/II study eribulin mesylate and lapatinib for metastatic in patients with human epidermal growth factor receptor 2-positive breast cancer previously treated with an anthracycline, taxane and trastuzumab - Phase I/II study eribulin mesylate and lapatinib
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- nresectable advanced or recurrent breast cancer
- Sponsor
- ational Cancer Center Hospital
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •a)Patients with brain metastases with symptoms b)Patients with the body cavity fluid marked (pleural effusion, ascites, pericardial effusion). However, it can be registered if good control due to the administration of adhesion agent. c)Patients with synchronous double cancer, not including lesions equivalent to carcinoma in situ or mucosal carcinoma considered healed with topical therapy d)Patients with complications is determined causing serious problems in the implementation of treatment \- Patients with poor control diabetes \- Patients with activity infection \- Patients with pulmonary fibrosis or interstitial pneumonia on chest X\-ray \- Patient with protocol difficult\-to\-treat caused by the mental state or neuropsychiatric disorders \- Patients with watery diarrhea chronic \- Patients with ileus, significant bleeding tendency, and gastrointestinal bleeding \- Patients with uncontrolled angina and myocardial infarction and heart disease merger severe cases with heart failure that developed within three months e)Pregnant or breast\-feeding women, or women of child bearing potential who intend to become pregnant
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
This is a Phase 1 Study of Eribulin Mesylate in Pediatric Patients With Recurrent or Refractory Solid Tumors (Excluding CNS), Including Lymphomas.Solid Tumors including LymphomasTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-001894-34-Outside-EU/EEAEisai Inc.23
Completed
Phase 1
Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast CancerEstrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor-negativeStage IV Breast CancerTriple-negative Breast CarcinomaNCT02120469City of Hope Medical Center27
Completed
Phase 1
Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung CancerNon Small Cell Lung CancerNCT01126736Eisai Inc.98
Terminated
Phase 2
Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast CancerHER2-positive Breast CancerMetastatic Breast CancerNCT01912963Dana-Farber Cancer Institute32
Active, not recruiting
Phase 1
Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by SurgeryLiposarcomaMalignant Abdominal NeoplasmMalignant Retroperitoneal NeoplasmMalignant Scrotal NeoplasmMalignant Solid NeoplasmMalignant Spermatic Cord NeoplasmNCT03361436OHSU Knight Cancer Institute15